| URL | https://bioprocessintl.com/bioprocess-insider/faci |
| Source | BioProcess Intl |
| Date Published | 06/23/2022 |
| Author Name | Millie Nelson |
| Mentions specific company case(s) of reshoring, kept from offshoring, or transplant | Yes |
| Company/Division name | Tenaya |
| Parent company | Tenaya |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Total number of jobs (added or to be added): | 180 |
| Year reshoring announced: | 2021 |
| Year reshoring implemented or to be implemented: | 2022 |
| Capital investment ($): | 106 |
| City reshored to: | union City |
| State(s) reshored to: | CA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | AAV gene therapy |
| What domestic positive factors made reshoring more attractive? | Customization/Flexibility, Eco-system synergies, Infrastructure, Impact on domestic economy, Lead time/Time to market, Proximity to customers/market, Skilled workforce availability/training |